MoonLake Immunotherapeutics MLTX Products & Services — Variable consideration amount

Similar metrics at other companies

SUPNLicense — Revenue, remaining performance obligation, variable consideration amount

$470M—

SEPNResearch Development Programs And Manufacturing Services — Variable Consideration

$10.3M+122%

BCRXLicense and other revenues — Contract with customer, transaction price

$2.4M—

SEPNDiscovery Research Milestones — Variable Consideration

$2M—

CRNXLicense — Milestone revenue

$1.5M—

STOKLicense — Revenue

$2.88M-60.9%

Questions, answered.

What is MoonLake Immunotherapeutics's products & services — variable consideration amount?

MoonLake Immunotherapeutics (MLTX) reported products & services — variable consideration amount of $8.1M in Q1 2026.

How has MoonLake Immunotherapeutics's products & services — variable consideration amount changed year-over-year?

MoonLake Immunotherapeutics's products & services — variable consideration amount decreased by 0.0% year-over-year, from $8.1M to $8.1M.

What is the long-term trend for MoonLake Immunotherapeutics's products & services — variable consideration amount?

Over 2 years (2023 to 2025), MoonLake Immunotherapeutics's products & services — variable consideration amount has grown at a -81.8% compound annual growth rate (CAGR), from $976.3M to $32.4M.

What does products & services — variable consideration amount mean?

This metric quantifies the total variable consideration allocated to the license segment that is subject to future performance-based outcomes. It captures the portion of contract revenue that is uncertain and dependent on the successful progression of drug development programs or market-based triggers. Monitoring this amount helps investors assess the upside potential embedded in current licensing partnerships and the company's exposure to future milestone-driven cash flows.